Back

Sacubitril/Valsartan: for all patients?

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Bebiana Faria

Hospital Guimaraes, Guimaraes (Portugal)

56 More presentations in this session

Presentation thumbnail
Effects of mineralocorticoid ceceptor antagonists (MRA) in heart failure patients after up to 12 months of follow-up.
Doctor L. Borg (Msida, MT)
Abstract
Presentation thumbnail
Sacubitril valsartan, a multicentric experience
Mr F. Cortes (Sevilla, ES)
Abstract
Presentation thumbnail
Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy
Professor B. Kanazirev (Varna, BG)
Abstract Slides
Presentation thumbnail
Effects of sacubitril/valsartan on real-world patients with heart failure due to non-ischemic cardiomyopathy
Associate Professor C. Hsu (Taipei, TW)
Abstract Slides
Presentation thumbnail
Effects of ivabradine on patients with depressed left ventricular ejection fraction after cardiac resynchronization therapy
Doctor C. Hsieh (Taipei, TW)
Abstract

Access the full session

Session thumbnail
Poster Session 3 - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources